You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Last Updated: February 25, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for BGB-A317

Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

What is the drug development status for BGB-A317?

BGB-A317 is an investigational drug.

There have been 59 clinical trials for BGB-A317. The most recent clinical trial was a Phase 1 trial, which was initiated on January 25th 2017.

The most common disease conditions in clinical trials are Lymphoma, Carcinoma, and Neoplasms. The leading clinical trial sponsors are BeiGene, BeiGene USA, Inc., and Celgene.

There are two US patents protecting this investigational drug.

Recent Clinical Trials for BGB-A317
Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular CarcinomaNational Taiwan University Hospital, Yun-Lin BranchPhase 2
Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular CarcinomaNational Taiwan University HospitalPhase 2
Efficacy and Safety of Zanubrutinib Plus Tislelizumab for Treatment of Patients With Richter TransformationGerman CLL Study GroupPhase 2

See all BGB-A317 clinical trials

Clinical Trial Summary for BGB-A317

Top disease conditions for BGB-A317
Top clinical trial sponsors for BGB-A317

See all BGB-A317 clinical trials

US Patents for BGB-A317

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
BGB-A317   Start Trial Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment Bristol-Myers Squibb Company (Princeton, NJ) Celldex Therapeutics, Inc. (Hampton, NJ)   Start Trial
BGB-A317   Start Trial Combination therapy with an anti-axl antibody-drug conjugate ADC THERAPEUTICS SA (Epalinges, CH) MEDIMMUNE LIMTIED (Cambridge, GB)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.